Results 251 to 260 of about 233,740 (307)

CD19-negative relapse with an apparent cytogenetic shift after blinatumomab-induced measurable residual disease clearance in Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia. [PDF]

Leuk Res Rep
Saburi M, Nagano R, Maruyama R, Sakata M, Takata H, Ohtsuka E.   +5 more
europepmc   +1 more source

Inflammatory and Immunological Basis of Periodontal Diseases

Journal of Periodontal Research, EarlyView.
The periodontal lesion emerges as an evolving immunological battlefield, where host–microbiome interactions, dysregulated immune responses, fragile resolution mechanisms, and inflammophilic dysbiosis converge to shift the balance from homeostasis to unrestrained tissue destruction.
Giacomo Baima, Marion Arce, Mario Romandini, Thomas Van Dyke   +3 more
wiley   +1 more source

Progress of Myeloid-Associated Antigens Such as CD7 and CD19 in AML

Advances in Clinical Medicine
openaire   +1 more source

Advances in CAR-T Cell Therapy: From Structural Design Innovations to Clinical Translation Challenges. [PDF]

J Cancer
Gao H, Fang Y, Zhang P, Qian Q.
europepmc   +1 more source

The lymphocyte function of allogeneic peripheral blood stem cell grafts is associated with relapse and cytomegalovirus reactivation

Transfusion, EarlyView.
Abstract Background Allogeneic hematopoietic stem cell transplantation (HSCT) is a treatment primarily for hematological malignancies. Infections, relapse, and graft versus host disease (GvHD) are some of the most common adverse events following HSCT. We aimed to evaluate whether the lymphocyte function of the stem cell graft was associated with these ...
Anna Söderström, Tengyu Wang, Johan Törlén, Hannes Lindahl, Davide Valentini, Stephan Mielke, Klara Asplund Högelin, Rebecca Axelsson Robertson, Michael Uhlin   +8 more
wiley   +1 more source

A versatile and GMP-compliant bead-based IFN-γ potency assay for standardized quality control and release testing of CAR-T cell drug products. [PDF]

Int J Pharm X
Dennebos R, González-Corrales M, Lysandrou M, Smit NAM, Qi Y, van Meerten T, Kosterink JGW, Huls G, Lourens HJ, Gareb B, Bremer E.   +10 more
europepmc   +1 more source

Challenges and opportunities: CAR-T cell therapy in autoimmune diseases. [PDF]

Cell Insight
Yan R, Ye S, Xu H.
europepmc   +1 more source

Engineering programmable CAR and antigen pairing via drug-gated light activation. [PDF]

Nat Commun
Huang Z, Limsakul P, Wu Y, Guo T, Wang Y, Wu Z, Zhu L, Allen ME, Liu L, Wang Y.   +9 more
europepmc   +1 more source

Chimeric Antigen Receptor T-Cell Revolution Remodeling Immunity to Conquer Autoimmune Disease. [PDF]

Research (Wash D C)
Shao W, Liu J, Sun M, Yu D.
europepmc   +1 more source

Dual-target CAR-T cell therapy: latest updates from the 2025 ASH annual meeting. [PDF]

Exp Hematol Oncol
Feng S, Kong R, Xiao L, Zhou X.
europepmc   +1 more source